Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.59 |
| ▸ | HTR2A | P28223 | 4/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6946976 | 0.87 | SLC6A4 (0.72) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6947521 | 0.82 | SLC6A4 (0.64) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL3696560 | 0.80 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3KDM4EPOLB | |
| SCHEMBL29888844 | 0.80 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3KDM4EPOLB | |
| SCHEMBL2562283 | 0.80 | HSD17B10 (0.57) | KDM4EPOLBMAOBALDH1A1 | |
| SCHEMBL2562353 | 0.79 | KDM4E (0.52) | SLC6A4SLC6A2SLC6A3KDM4EPOLB | |
| SCHEMBL6946108 | 0.74 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6947187 | 0.74 | SLC6A4 (0.70) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL14097989 | 0.73 | PTGDR2 (0.49) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL14097988 | 0.73 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-04-15 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | SLC6A4 34/4885SLC6A2 71/4885SLC6A3 226/4885 |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | SLC6A4 4537/4885SLC6A2 3501/4885SLC6A3 4289/4885 |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, RNASE1, EIF2AK2 | SLC6A4 4825/4885SLC6A2 4758/4885SLC6A3 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.